Literature DB >> 1390332

Long-term hemodynamic effects of nifedipine on congenital heart disease with Eisenmenger's mechanism in children.

M Wimmer1, M Schlemmer.   

Abstract

The hemodynamic effect of long-term nifedipine medication was studied in 10 children, 3-12 years of age, five with ventricular septal defect and five with complete atrioventricular septal defect; all had Eisenmenger's reaction, seven also had Down's syndrome. They underwent heart catheterization prior to and during 1-4 years of nifedipine therapy. Fick's principle was used to calculate the ratio of pulmonary arterial pressure to aortic pressure (PAP/PAO), the ratio of pulmonary flow to aortic flow (QP/QS), as well as the ratio of pulmonary vascular resistance to aortic vascular resistance (RP/RS). In the seven children under 8.8 years, nifedipine caused a significant drop in PAP/PAO (p less than 0.004), a slight increase in arterial O2 saturation, a significant increase in QP/QS (p less than 0.02), and a decrease in RP/RS (p less than 0.02). The nifedipine effect was age related. On nifedipine, breathing oxygen resulted in, independent of age, a significant increase in QP/QS (p less than 0.003) and a significant decrease in PAP/PAO (p less than 0.04) and in RP/RS (p less than 0.003). Direct O2 consumption measurements before and during oxygen breathing in six patients demonstrated no significant change in RP, RS, QP, or QS indices. Nifedipine had a relaxing effect on the pulmonary vascular bed, especially in the younger child with Eisenmenger's mechanism. On nifedipine therapy, O2 produced a more complex hemodynamic reaction that was not restricted to the pulmonary circulation alone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1390332     DOI: 10.1007/bf00054569

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  12 in total

1.  The Eisenmenger syndrome. A clinical and physiologic reappraisal.

Authors:  H L Brammell; J H Vogel; R Pryor; S G Blount
Journal:  Am J Cardiol       Date:  1971-12       Impact factor: 2.778

2.  The estimation of oxygen consumption.

Authors:  C G LaFarge; O S Miettinen
Journal:  Cardiovasc Res       Date:  1970-01       Impact factor: 10.787

3.  Systemic vasoconstrictor effects of oxygen administration in obliterative pulmonary vascular disorders.

Authors:  M Packer; W H Lee; N Medina; M Yushak
Journal:  Am J Cardiol       Date:  1986-04-01       Impact factor: 2.778

4.  [Spontaneous evolution and complication of the Eisenmenger syndrome].

Authors:  A Davido; I Touzet; A Corone; J L Jullien; P Corone
Journal:  Arch Mal Coeur Vaiss       Date:  1983-05

5.  [Hemodynamic studies of nifedipine (Adalat) in pulmonary hypertension in childhood].

Authors:  M Wimmer; M Schlemmer; F Ebner
Journal:  Wien Klin Wochenschr       Date:  1986-11-07       Impact factor: 1.704

6.  Endothelial function in clinical pulmonary hypertension.

Authors:  R J Barst; S A Stalcup
Journal:  Chest       Date:  1985-10       Impact factor: 9.410

7.  Cardiovascular effects of breathing 95 percent oxygen in children with congenital heart disease.

Authors:  R H Beekman; A P Rocchini; A Rosenthal
Journal:  Am J Cardiol       Date:  1983-07       Impact factor: 2.778

8.  Pulmonary vascular disease in children with congenital cardiovascular malformations. Etiologic considerations.

Authors:  G M Folger
Journal:  Angiology       Date:  1983-12       Impact factor: 3.619

9.  Hemodynamic effects of nifedipine and oxygen in children with pulmonary hypertension.

Authors:  M Wimmer; M Schlemmer; F Ebner
Journal:  Cardiovasc Drugs Ther       Date:  1988-12       Impact factor: 3.727

10.  Effect of long term oxygen treatment at home in children with pulmonary vascular disease.

Authors:  J J Bowyer; C M Busst; D M Denison; E A Shinebourne
Journal:  Br Heart J       Date:  1986-04
View more
  4 in total

1.  Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome.

Authors:  W Budts; N Van Pelt; H Gillyns; M Gewillig; F Van De Werf; S Janssens
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

2.  Cardiac catheterization in children with pulmonary hypertensive vascular disease: consensus statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces.

Authors:  Maria Jesus Del Cerro; Shahin Moledina; Sheila G Haworth; Dunbar Ivy; Maha Al Dabbagh; Hanaa Banjar; Gabriel Diaz; Alexandria Heath-Freudenthal; Ahmed Nasser Galal; Tilman Humpl; Snehal Kulkarni; Antonio Lopes; Ana Olga Mocumbi; G D Puri; Beyra Rossouw; S Harikrishnan; Anita Saxena; Patience Udo; Lina Caicedo; Omar Tamimi; Ian Adatia
Journal:  Pulm Circ       Date:  2016-03       Impact factor: 3.017

Review 3.  Etiology, diagnosis, and pharmacologic treatment of pediatric pulmonary hypertension.

Authors:  Robert Tulloh
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

4.  The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part II: Medical Treatment - Study Results.

Authors:  Siegrun Mebus; Ingram Schulze-Neick; Erwin Oechslin; Koichiro Niwa; Pedro T Trindade; Alfred Hager; John Hess; Harald Kaemmerer
Journal:  Curr Cardiol Rev       Date:  2010-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.